Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Stage I Prostate Adenocarcinoma AJCC v7 1Prostatic Neoplasms 1Prostate Adenocarcinoma 1

Interventions

Specimen Handling 631pembrolizumab 610Magnetic Resonance Spectroscopy 553Carboplatin 450Cisplatin 398Cyclophosphamide 397Biopsy 375Nivolumab 326Paclitaxel 324Gemcitabine 317Radiotherapy 286Bevacizumab 244Dexamethasone 222fludarabine 215Docetaxel 199durvalumab 195venetoclax 188Oxaliplatin 187atezolizumab 184Fluorouracil 177Rituximab 176Pemetrexed 173Capecitabine 169Radiation 167Doxorubicin 166Radiosurgery 159Ipilimumab 147Etoposide 142Leucovorin 141Lenalidomide 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Salicylic Acid × 90 days × Clear all
NCT03070886 2026-05-07

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

NRG Oncology

Phase 2/3 Completed
612 enrolled
Genitourinary

Stage I Prostate Adenocarcinoma AJCC v7

NCT04513717 2026-05-04

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

NRG Oncology

Phase 3 Active not recruiting
2,753 enrolled
Genitourinary

Prostatic Neoplasms

NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡